The effects of orlistat in patients with diabetes: improvement in glycaemic control and weight loss
The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: In addition to direct weight reduction, there may be other benefits of obesity treatment including improved insulin sensitivity. The purpose of this study was to characterise concomitant diabetes drug use and the related costs in patients with diabetes treated with orlistat (Xenical) in the first 6 months of treatment. METHODS: One hundred overweight patients with diabetes and a body mass index (BMI) > or = 28 kg/m2 were enrolled in a structured UK hospital-based weight management clinic and treated with orlistat plus behavioural interventions. Among other measures, weight, glucose control (HbA1c) and drug treatment were recorded. Subjects were followed-up for a maximum of 24 months at intervals of 1-3 months, with a maximum treatment period of 24 months. RESULTS: The majority of subjects (91%) had type 2 diabetes. They had a mean age of 55 years and 55% were women. For patients followed up at 6 months, their mean BMI at baseline was 39.5 kg/m2 with a mean HbA1c of 7.6%. The mean weight loss at 6 months was 7.1 kg (p < 0.001). Despite a significant average absolute HbA1c reduction of 0.62% (p < 0.001), the most notable gains were made by those with the highest baseline HbA1c values (a mean relative reduction of 20% for those above the 75th percentile). There were 50 patients treated with insulin at baseline and 47 at 6 months. Of those treated with insulin, the mean dose was 130 units at baseline and 90 units at 6 months (p < 0.001). Twenty patients (44.4%) initially treated with oral hypoglycaemic agents alone reduced their dose after 6 months (not significant). Despite marked improvement in insulin sensitivity (baseline mean, 1.24 units/kg; 6 month mean, 0.90 units/kg [p < 0.001]) there was no correlation with BMI change. The average cost of diabetes treatment at baseline was pound 1.16 per day and pound 0.83 at 6 months (p < 0.001). Age was the only independent predictor for insulin dose reduction. CONCLUSIONS: Orlistat appears to reduce the need for concomitant diabetes medication irrespective of weight loss, a reduction that is likely to represent a large cost offset for orlistat treatment.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873
Stratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059
Overweight and obesity in the United States: prevalence and trends, 1960–1994
Flegal, K., Carroll, M., Kuczmarski, R., & Johnson, C. (1998) · International Journal of Obesity · doi:10.1038/sj.ijo.0800541 · Cited by 3,045
Sjöström, L., Rissanen, A., Andersen, T., Boldrin, M., Golay, A., Koppeschaar, H. P., & Krempf, M. (1998) · The Lancet · doi:10.1016/s0140-6736(97)11509-4 · Cited by 1,237
Calle, E. E., & Thun, M. J. (2004) · Oncogene · doi:10.1038/sj.onc.1207751 · Cited by 769
Hollander, P. A., Elbein, S. C., Hirsch, I. B., Kelley, D., McGill, J., Taylor, T., Weiss, S. R., Crockett, S. E., Kaplan, R. A., Comstock, J., et al. (1998) · Diabetes Care · doi:10.2337/diacare.21.8.1288 · Cited by 654
Weight Change and Diabetes Incidence: Findings from a National Cohort of US Adults
Ford, E. S., Williamson, D. F., & Liu, S. (1997) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a009256 · Cited by 624
Redefining Type 2 diabetes: ‘Diabesity’ or ‘Obesity Dependent Diabetes Mellitus’?
Astrup, A., & Finer, N. (2000) · Obesity Reviews · doi:10.1046/j.1467-789x.2000.00013.x · Cited by 428 · cited 3×
“© 2005 LIBRAPHARM LTD – Curr Med Res Opin 2005; 21(11) Effect of orlistat on glycaemic control Rowe et al.”
BackgroundInfluentialHeymsfield, S. B., Segal, K. R., Hauptman, J., Lucas, C. P., Boldrin, M. N., Rissanen, A., Wilding, J. P. H., & Sjöström, L. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.9.1321 · Cited by 358
Guerciolini, R. (1997) · PubMed · Cited by 331
Research works printed but not linked: 3
- Guerciolini R, 1997, Int J Obes Relat Metab Disord, 21, S12
- Hollander PA, 1998, A 1-year randomized double-blind study. Diabetes Care, 21, 1288
- Miles JM, 1671, Diabetes Care, 2002, 25
Cited by
Orlistat-Associated Adverse Effects and Drug Interactions: A Critical Review
Filippatos, T. D., Derdemezis, C. S., Gazi, I. F., Nakou, E. S., Mikhailidis, D. P., & Elisaf, M. S. (2008) · Drug Safety · doi:10.2165/00002018-200831010-00005 · Cited by 434
The Diabetes Remission Clinical Trial (DiRECT): protocol for a cluster randomised trial
Leslie, W. S., Ford, I., Sattar, N., Hollingsworth, K. G., Adamson, A., Sniehotta, F. F., McCombie, L., Brosnahan, N., Ross, H., Mathers, J. C., et al. (2016) · BMC Family Practice · doi:10.1186/s12875-016-0406-2 · Cited by 132
“There is consistent evidence that modest sustained weight loss, using a variety of diet and lifestyle approaches to achieve 5–10 % weight loss, will prevent the onset of most new cases of T2DM in those with prediabetes [6, 7], and that it improves all aspects of diabetes control (glycaemia, blood pressure, lipids and…”
BackgroundInsulin-associated weight gain in obese type 2 diabetes mellitus patients: What can be done?
Brown, A., Guess, N., Dornhorst, A., Taheri, S., & Frost, G. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13009 · Cited by 113
Orlistat: A Review of its Use in the Management of Obesity
Henness, S., & Perry, C. M. (2006) · Drugs · doi:10.2165/00003495-200666120-00012 · Cited by 135
Avenell, A., Robertson, C., Skea, Z., Jacobsen, E., Boyers, D., Cooper, D., Aceves-Martins, M., Retat, L., Fraser, C., Aveyard, P., et al. (2018) · Health Technology Assessment · doi:10.3310/hta22680 · Cited by 99
Metadata
- Authors
- Rowe, R., Cowx, M., Poole, C., McEwan, P., Morgan, C., & Walker, M.
- Affiliations
- Wythenshawe Hospital (GB)
- Cardiff University (GB)
- Roche (United Kingdom) (GB)
- Corresponding author
- McEwan, Phil
- Venue
- Current Medical Research and Opinion
- Publisher
- Informa Healthcare
- Published
- 2005-10-18
- Volume
- 21
- Issue
- 11
- Pages
- 1885-1890
- ISSN
- 0300-7995 (ISSN-L)
- 1473-4877
- OpenAlex
- W2155052156
- Semantic Scholar
- b908e0fa818927b93100239df6e4a79f0ff77237
- Cited by
- 28
- References
- 27
- Citations by year
- 2024: 1 · 2022: 3 · 2021: 1 · 2020: 1 · 2019: 2 · 2018: 2 · 2017: 3 · 2016: 2 · 2012: 1
- FWCI
- 1.70
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Current Medical Research and Opinion (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- orlistat, type 2 diabetes, glycemic control, HbA1c, weight loss, obesity, insulin dose reduction, insulin sensitivity, weight management clinic, behavioral interventions, overweight patients, drug interactions, cost-effectiveness, body mass index, oral antidiabetic drugs
- MeSH terms
- Orlistat, Adult, Aged, Aged, 80 and over, Blood Glucose, Diabetes Mellitus, Type 2, Female, Follow-Up Studies, Humans, Hypoglycemic Agents, Lactones, Male, Middle Aged, Obesity, Prospective Studies, Weight Loss, Body Mass Index, Anti-Obesity Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The effects of orlistat in patients with diabetes: improvement in glycaemic control and weight loss. https://app.cochat.ai/papers/10.1185/030079905x74943
- The paper
- Rowe, R., Cowx, M., Poole, C., McEwan, P., Morgan, C., & Walker, M. (2005). The effects of orlistat in patients with diabetes: improvement in glycaemic control and weight loss. Current Medical Research and Opinion. https://doi.org/10.1185/030079905x74943
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.